Antibiotic Eye Ointments: Uses, Side Effects, Dosages
The Genetics Of Open-angle Glaucoma: The Story Of GLC1A And Myocilin
Quigley HA . Number of people with glaucoma worldwide. Br J Ophthalmol 1996;80:389–93
Leske MC . The epidemiology of open-angle glaucoma: a review. Am J EpidemioI 1983;118:166–91
Leighton DA . Survey of the first-degree relatives of glaucoma patients. Trans Ophthalmol Soc UK 1976;96:28–32
Miller SJH, Paterson GD . Studies on glaucoma relatives. Br J Ophthalmol 1962;46:513–22
Dryja TP, McGee TL, Hahn LB, Cowley GS, Yandell DW, Sandberg MA . A point mutation of the rhodopsin gene in one form of retinitis pigmentosa. Nature 1990;343:364–6
Nishimura DY, Swiderski RE, Alward WL, Searby CC, Patil SR, Bennet SR, et al . The forkhead transcription factor gene FKHL7 is responsible for glaucoma phenotypes which map to 6p25. Nature Genet 1998;19:140–7
Mears AJ, Jordan T, Mirzayans F, Dubois S, Kume T, Parlee M, et al . Mutations of the forkhead/winged-helix gene, FKHL7, in patients with Axenfeld-Rieger anomaly. Am J Hum Genet 1998;63:1316–28
Murray JC, Bennett SR, Kwitek AE, Small KW, Schinzel A, Alward WLM, et al . Linkage of Rieger syndrome to the region of the epidermal growth factor gene on chromosome 4. Nature Genet 1992;2:46–9
Stone EM, Fingert JH, Alward WLM, Nguyen TD, Polansky JR, Sunden SLF, et al . Identification of a gene that causes primary open angle glaucoma. Science 1997;275:668–70
Mardin CY, Velten I, Ozbey S, Rautenstrauss B, Michels- Rautenstrauss K . A GLCIA gene GLN368Stop mutation in a patient with normal-tension open-angle glaucoma. J Glaucoma 1999;8:154–6
Sheffield VC, Stone EM, Alward WLM, Drack AV, Johnson AT, Streb LM, et al . Genetic linkage of familial open angle glaucoma to chromosome lq21-q31. Nature Genet 1993;4:47–50
Collins FS . Positional cloning moves from perditional to traditional. Nature Genet 1995;9:347–50
Johnson AT, Drack AV, Kwitek AE, Cannon RL, Stone EM, Alward WLM . Clinical features and linkage analysis of a family with autosomal dominant juvenile glaucoma. Ophthalmology 1993;100:524–9
Richards JE, Lichter PR, Boehnke ML, Uro J, Torrez D, Wong D, et al . Mapping of a gene for autosomal dominant juvenile-onset primary open-angle glaucoma to chromosome lq. Am J Hum Genet 1994;54:62–70
Wiggs JL, Haines JL, Paglinauan C, Fine A, Sporn C, Lou D . Genetic linkage of autosomal dominant juvenile glaucoma to lq21-q31 in three affected pedigrees. Genomics 1994;21:299–303
Graff C, Urbak SF, Jerndal T, Wadelius C . Confirmation of linkage to 1q21-31 in a Danish autosomal dominant juvenile-onset glaucoma family and evidence of genetic heterogeneity. Hum Genet 1995;96:285–9
Lichter PR, Richards JE, Boehnke M, Othman M, Cameron BD, Stringham HM, et al . Juvenile glaucoma linked to the GLCIA gene on chromosome lq in a Panamanian family. Am J Ophthalmol 1997;123:413–6
Morissette J, Côté G, Anctil J-L, Plante M, Amyot M, Héon E, et al . A common gene for juvenile and adult-onset primary open-angle glaucomas confined to chromosome 1q. Am J Hum Genet 1995;56:1431–42
Brezin AP, Bechetoille A, Hamard P, Valtot F, Berkani M, Belmouden A, et al . Genetic heterogeneity of primary open angle glaucoma and ocular hypertension: linkage to GLCIA associated with an increased risk of severe glaucomatous optic neuropathy. J Med Genet 1997;34:546–52
Sunden SLF, Alward WLM, Nichols BE, Rokhlina TR, Nystuen A, Stone EM, et al . Fine mapping of the autosomal dominant juvenile open angle glaucoma (GLCIA) region and evaluation of candidate genes. Genome Res 1996;6:862–9
Polansky JR, Fauss DJ, Chen P, Chen H, Lutjen-Drecoll E, Johnson D, et al . Cellular pharmacology and molecular biology of the trabecular meshwork inducible glucocorticoid response gene product. Ophthalmologica 1997;211:126–39
Alward WL, Fingert JH, Coote MA, Johnson AT, Lerner SF, Junqua D, et al . Clinical features associated with mutations in the chromosome 1 open-angle glaucoma gene (GLCIA) [see comments]. N Engl J Med 1998;338:1022–7
Adam MF, Belmouden A, Binisti P, Brezin AP, Valtot F, Bechetoille A, et al. Recurrent mutations in a single exon encoding the evolutionary conserved olfactomedin-homology domain of TIGR in familial open-angle glaucoma. Hum Mol Genet 1997;6:2091–7
Angius A, De Gioia E, Loi A, Fossarello M, Sole G, Orzalesi N, et al . A novel mutation in the GLC1A gene causes juvenile open-angle glaucoma in 4 families from the Italian region of Puglia. Arch Ophthalmol 1998;116:793–7
Brezin AP, Adam MF, Belmouden A, Lureau MA, Chaventre A, Copin B, et al . Founder effect in GLCIA-linked familial open-angle glaucoma in Northern France. Am J Med Genet 1998;76:438–45
Kennan AM, Mansergh FC, Fingert JH, Clark T, Ayuso C, Kenna PF, et al . A novel Asp380Ala mutation in the GLCIA/ myocilin gene in a family with juvenile onset primary open angle glaucoma. J Med Genet 1998;35:957–60
Fingert JH, Ho E, Liebmann JM, Yamamoto T, Craig JE, Rait J, et al . Analysis of myocilin mutations in 1703 glaucoma patients from five different populations. Hum Mol Genet 1999;8:899–905
Yoon SJ, Kim HS, Moon JI, Lim JM, Joo CK . Mutations of the TIGR/MYOC gene in primary open-angle glaucoma in Korea [letter]. Am J Hum Genet 1999;64:1775–8
Stoilova D, Child A, Brice G, Desai T, Barsoum-Homsy M, Ozdemir N, et al . Novel TIGR/MYOC mutations in families with juvenile onset primary open angle glaucoma. J Med Genet 1998;35:989–92
Suzuki Y, Shirato S, Taniguchi F, Ohara K, Nishimaki K, Ohta S . Mutations in the TIGR gene in familial primary open-angle glaucoma in Japan. Am J Hum Genet 1997;61:1202–4
Stoilova D, Child A, Brice G, Crick RP, Fleck BW, Sarfarazi M . Identification of a new 'TIGR'mutation in a family with juvenile-onset primary open angle glaucoma. Ophthalmic Genet 1997;18:109–18
Mansergh FC, Kenna PF, Ayuso C, Kiang A-S, Humphries P, Farrar GJ . Novel mutations in the TIGR gene in early and late onset open angle glaucoma. Hum Mutat 1998;11:244–51
Kubota R, Noda S, Wang Y, Minoshima S, Asakawa S, Kudoh J, et al . A novel myosin-like protein (myocilin) expressed in the connecting cilium of the photoreceptor: molecular cloning, tissue expression, and chromosomal mapping. Genomics 1997;41:360–9
Bal RS, Anholt RR . Formation of the extracellular mucous matrix of olfactory neuroepithelium: identification of partially glycosylated and nonglycosylated precursors of olfactomedin. Biochemistry 1993;32:1047–53
Lutjen-Drecoll E, May CA, Polansky JR, Johnson DH, Bloemendal H, Nguyen TD . Localization of the stress proteins alpha B-crystallin and trabecular meshwork inducible glucocorticoid response protein in normal and glaucomatous trabecular meshwork. Invest Ophthalmol Vis Sci 1998;39:517–25
Fingert JH, Ying L, Swiderski RE, Nystuen AM, Arbour NC, Alward WLM, et al . Characterization and comparison of the human and mouse GLC1A glaucoma genes. Genome Res 1998;8:377–84
Swiderski RE, Ying L, Cassell MD, Alward WL, Stone EM, Sheffield VC . Expression pattern and in situ localization of the mouse homologue of the human MYOC (GLC1A) gene in adult brain. Mol Brain Res 1999;68:64–72
Clark A, English-Wright S, Lane D, Steely H, Fingert J, Stone E . Expression of the glaucoma gene myocilin in cells of the human optic nerve head. Invest Ophthalmol Vis Sci (Suppl) 1999;40:S673.
Borras T, Matsumoto Y, Epstein DL, Johnson DH . Gene transfer to the human trabecular meshwork by anterior segment perfusion. Invest Ophthalmol Vis Sci 1998;39:1503–7
Borras T, Rowlette L, Erzurum S, Epstein D . Adenoviral reporter gene transfer to the human trabecular meshwork does not alter aqueous humor outflow: relevance for potential gene therapy of glaucoma. Gene Therapy 1999;6:515–24
Stoilova D, Child A, Trifan OC, Crick RP, Coakes RL, Sarfarazi M . Localization of a locus (GLC1B) for adult-onset primary open angle glaucoma to the 2cen-q13 region. Genomics 1996;36:142–50
Wirtz MK, Samples JR, Kramer PL, Rust K, Topinka JR, Yount J, et al . Mapping a gene for adult-onset primary open-angle glaucoma to chromosome 3q [see comments]. Am J Hum Genet 1997;60:296–304
Trifan OC, Traboulsi EI, Stoilova D, Alozie I, Nguyen R, Raja S, et al . A third locus (GLC1D) for adult-onset primary open-angle glaucoma maps to the 8q23 region. Am J Ophthalmol 1998;126:17–28
Sarfarazi M, Child A, Stoilova D, Brice G, Desai T, Trifan OC, et al . Localization of the fourth locus (GLC1E) for adult-onset primary open-angle glaucoma to the 10p15-p14 region. Am J Hum Genet 1998;62:641–52
Wirtz MK, Samples JR, Rust K, Lie J, Nordling L, Schilling K, et al . GLC1F, a new primary open-angle glaucoma locus, maps to 7q35-q36. Arch Ophthalmol 1999;117:237–41
Michels-Rautenstrauss KG, Mardin CY, Budde WM, Liehr T, Polansky J, Nguyen T, et al . Juvenile open angle glaucoma: fine mapping of the TIGR gene to 1q24.3--q25.2 and mutation analysis. Hum Genet 1997;102:103–6
Angius A, De Gioia E, Loi A, Fossarello M, Sole G, Orzalesi N, et al . A novel mutation in the GLC1A gene causes juvenile open-angle glaucoma in 4 families from the Italian region of Puglia. Arch Ophthalmol 1998;116:793–7
Rozsa FW, Shimizu S, Lichter PR, Johnson AT, Othman MI, Scott K, et al . GLC1A mutations point to regions of potential functional importance on the TIGR/MYOC protein. Mol Vis 1998;4:20.
Richards JE, Ritch R, Lichter PR, Rozsa FW, Stringham HM, Caronia RM, et al . Novel trabecular meshwork inducible glucocorticoid response mutation in an eight-generation juvenile-onset primary open-angle glaucoma pedigree. Ophthalmology 1998;105:1698–707
Kee C, Ahn BH . TIGR gene in primary open-angle glaucoma and steroid-induced glaucoma. Korean J Ophthalmol 1997;11:75–8
Wiggs JL, Allingham RR, Vollrath D, Jones KH, De La Paz M, Kern J, et al . Prevalence of mutations in TIGR/Myocilin in patients with adult and juvenile primary open-angle glaucoma [letter]. Am J Hum Genet 1998;63:1549–52
Savvy Senior: Early Detection Key With Glaucoma
Dear Savvy Senior: What can you tell me about the eye disease glaucoma? My older brother was recently diagnosed with it and lost some of his vision, but never had a clue anything was wrong. Could I be at risk too?
— Stressed Sibling Dear Stressed: Yes. Having an immediate family member with glaucoma significantly increases your risks of developing it, but there are other risk factors you need to be aware. Too. Here's what you should know.
What is glaucoma?Glaucoma is a group of eye diseases that can damage the optic nerve and cause vision loss and blindness if it's not treated. This typically happens because the fluids in the eye don't drain properly, causing increased pressure in the eyeball.
But the scary thing about glaucoma is that with no early warning signs or pain, most people that have it don't realize it until their vision begins to deteriorate.
While there are two main types of glaucoma, the most common form that typically affects older adults is called open-angle glaucoma. This disease develops very slowly when the eye's drainage canals become clogged over time, leading to blind spots in the peripheral or side vision. By the time you notice it, the permanent damage is already done.
Are you at risk?It's estimated that more than 3 million Americans have glaucoma today, but that number is expected to surge to more than 6.3 million by 2050. If you answer "yes" to any of the following questions, you're at increased risk of developing it.
• Are you African American, Hispanic/Latino American or Asian American?
• Are you over age 60?
• Do you have an immediate family member with glaucoma?
• Do you have diabetes, heart disease, high blood pressure, migraines or have extreme nearsightedness or farsightedness?
• Have you had a past eye injury?
• Have you used corticosteroids (for example, eye drops, pills, inhalers, and creams) for long periods of time?
What to doEarly detection is the key to guarding against glaucoma. So, if you're age 40 or older and have any of the previously mentioned risk factors, especially if you're African American, you need to get a comprehensive eye examination every 18 to 24 months. Or, if you notice some loss of peripheral vision, get to the eye doctor right away.
If you're a Medicare beneficiary, annual eye examinations are covered for those at high risk for glaucoma. Or if you don't have vision coverage, contact EyeCare America, a national public service program that provides free glaucoma eye exams through a pool of more than 4,600 volunteer ophthalmologists. Visit AAO.Org/eyecare-america or call 877-887-6327 to learn more.
While there's currently no cure for glaucoma, most cases can be treated with prescription eye drops, which reduce eye pressure and can prevent further vision loss. It cannot, however, restore vision already lost from glaucoma. If eye drops don't work, your doctor may recommend oral medication, laser treatments, incisional surgery or a combination of these methods.
For more information on glaucoma, visit the National Eye Institute at NEI.Nih.Gov, and the Glaucoma Research Foundation at glaucoma.Org.
— Savvy Senior
Send your senior questions to Savvy Senior, P.O. Box 5443, Norman, OK 73070, or visit SavvySenior.Org. Jim Miller is a contributor to the NBC Today show and author of "The Savvy Senior" book.
Glaucoma Therapeutics Market Envisions A Future Valued At US$10.2 Million By 2032-FMI Projection
Glaucoma Therapeutics Market By 2022, the glaucoma therapeutics market growth is projected to be valued US$6.9 million. Glaucoma therapies are predicted to have overall demand develop at a CAGR of 3.7% between 2022 and 2032, reaching around US$ 10.2 million.
By treatment type, medication eye drops segment will hold the maximum market share for the global glaucoma therapeutic market due to its high preference by the physician for medication during the early stages of treatment.
Laser surgery is more preferred than tradition surgery by booth surgeon and the patients owing to the low risk of failure. By glaucoma type, closed glaucoma will dominate the maximum market share attributed to its more prevalence then open glaucoma.
Get a Sample Copy of the Report :https://www.Futuremarketinsights.Com/reports/sample/rep-gb-6456
Glaucoma Therapeutics Market: Drivers and Restraints:
The change in the lifestyle of people has resulted in the rise in the prevalence of glaucoma globally. Increasing prevalence of glaucoma is the primary factor driving the growth of glaucoma therapeutics market around the globe. Glaucoma is more prevalent among the people above the age of 60. Rising geriatric population thought the globe is also responsible for the robust growth of glaucoma therapeutics market over the forecast period. Increasing preference of physician towards the laser surgery for the treatment of glaucoma will propel the growth of glaucoma therapeutics market over the forecast period.
Less awareness among the people about the glaucoma treatment will deter the growth of glaucoma therapeutics market to some extent. Moreover, lack of availability of skilled professional for laser surgery in under developing economies will also hamper the growth of glaucoma therapeutics market. Glaucoma is the eye disease that damage the patient eye nerve optics. The formation extra fluid up in the front part of the eye results the damage to eye nerve optics. Glaucoma is of two type, primary open-angle glaucoma and angle-closure glaucoma which is also referred as closed-angle glaucoma or narrow-angle glaucoma.
Open-angle glaucoma is the most common type glaucoma. Primary glaucoma gradually happens when the eye does not drain the fluids.
This result the building of pressure on eye nerve optics. Open glaucoma causes no change in the eye vision and it is painless too.
Closed-angle glaucoma happens very close to the drainage angle which results the blocking of drainage angle of eyesight. This is a very acute type of glaucoma.
This type of glaucoma may affect the vision of the patient and it may cause severe pain to the eye and the headache.
Glaucoma is generally treated with eye drops, pill, traditional surgery, laser surgery and sometimes the combination of these methods.
The aim of glaucoma treatment is to avoid the vision loss of patient wherever if the vision of particular patient is already lost then it is irreversible by glaucoma treatment.
Unlock exclusive insights with our expert analysts:https://www.Futuremarketinsights.Com/ask-question/rep-gb-6456
Regular consumption of medication as prescribed by the physician is very necessary for the proper treatment of glaucoma.
The drugs of glaucoma have very fewer chances of effects which has increased it adoption the global market.
Glaucoma Therapeutics Market: Key Players
Some of player across the value chain of Glaucoma Therapeutics market are Novartis AG, Allergan, Merck & Co., Inc., Akorn, Inc., Bausch & Lomb Incorporated, Teva Pharmaceuticals, Pfizer and Santen and others.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data.
It also contains projections using a suitable set of assumptions and methodologies.
The research report provides analysis and information according to market segments such as geographies, application, and industry.
The report covers exhaust analysis on:
Regional analysis includes:
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Unlock Tailored Insights: Customize Your Report for Maximum Impact:https://www.Futuremarketinsights.Com/customization-available/rep-gb-6456
Glaucoma Therapeutics Market: Segmentation
The global Glaucoma Therapeutics market is classified on the basis of treatment type, glaucoma type, and geographic region.
Based on treatment type, Glaucoma Therapeutics market is segmented into following:
Based on glaucoma type, Glaucoma Therapeutics market is segmented into following:
Key Segments:
Glaucoma Therapeutics Market by Treatment Type:
Glaucoma Therapeutics Market by Glaucoma Type:
Glaucoma Therapeutics Market by Region:
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Nandini Singh Sawlani
Future Market Insights Inc.Christiana Corporate, 200 Continental Drive,Suite 401, Newark, Delaware – 19713, USAT: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.ComWebsite: https://www.Futuremarketinsights.ComLinkedInTwitterBlogsYouTube
Comments
Post a Comment